Can Liver Cancers Be Better Targeted Using Lab-Grown Mini-Tumors?

Liver cancers are among the deadliest in the world. Their treatment often remains ineffective due to the diversity of tumors and the lack of reliable models to study them. A recent breakthrough shows that it is possible to grow mini-tumors, called organoids, in the laboratory from tissues taken from patients with the three main types of liver cancer: hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and a rare combined form of both. These organoids faithfully reproduce the genetic characteristics and behavior of the original tumors, providing a valuable tool for testing personalized treatments.

Researchers have analyzed these mini-tumors in detail. They discovered that each type of cancer exhibits distinct biological features. Hepatocellular carcinoma heavily relies on lipid metabolism, a process essential for storing and transforming fats in the body. Intrahepatic cholangiocarcinoma, which is more aggressive, activates mechanisms that promote the migration and spread of cancer cells throughout the body. The mixed form, meanwhile, is distinguished by increased mitochondrial activity, as mitochondria are the powerhouses of cells.

These observations have made it possible to identify specific weaknesses in each type of tumor. For example, rosuvastatin, a drug commonly used to lower cholesterol, slows the growth of hepatocellular carcinoma organoids by disrupting their lipid metabolism. For intrahepatic cholangiocarcinoma, pemigatinib, an inhibitor targeting a protein involved in cell migration, reduces tumor aggressiveness. Finally, regorafenib, a treatment already approved for certain advanced cancers, weakens the organoids of the mixed form by impairing mitochondrial function.

These findings pave the way for more tailored treatments. Organoids allow for the rapid testing of the effectiveness of various drugs on tumors from different patients, taking into account their genetic particularities. This approach could significantly improve the management of liver cancers by offering targeted therapies rather than one-size-fits-all treatments. It also highlights the importance of considering each tumor as unique, even within the same type of cancer, to optimize the chances of therapeutic success.

Site Sources

Official Study Source

DOI: https://doi.org/10.1007/s13402-026-01190-w

Title: Single-cell transcriptomic mapping of patient-derived primary liver cancer organoids reveals molecular subtypes and guides precision drug targeting

Journal: Cellular Oncology

Publisher: Springer Science and Business Media LLC

Authors: Shipeng Dai; Jian Wu; Yue Chai; Zhouxiao Li; Yuchen Xie; Hongyu Wang; Ziyuan Liu; Yanshu He; Hengsong Cao; Weiwei Tang; Jintao Xu; Zongkang Zhang; Yongxiang Xia; Xuehao Wang; Li Liu; Xinyi Xia; Yun Gao